NCT03905811

A Pilot Study of Terazosin for Parkinson's Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Jordan Schultz · Academic / Other
• Sex: All
• Age: 40 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.

Detailed description

This will be a single center, randomized, double-blind, controlled, pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (MG) daily for patients with PD. The primary goal of this study is to assess the safety and tolerability of TZ in patients with PD. This is a pilot study and is not powered to assess efficacy of this medication. Our hope is that this study will guide future studies of this (and similar) medications for the disease modification of PD. This study is also aimed to learn more about how patients with produce and use energy and if TZ can help to reverse energy deficits that appear in PD.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	Terazosin 5 MG	5 milligrams by mouth daily at bedtime
DRUG	Placebo oral capsule	1 capsule by mouth daily at bedtime

Timeline

• Start date: 2019-09-24
• Primary completion: 2020-06-05
• Completion: 2020-11-18
• First posted: 2019-04-05
• Last updated: 2022-05-16
• Results posted: 2021-08-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study